We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adicet Bio, Inc. (ACET - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adicet Bio, Inc. is a member of our Medical group, which includes 920 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adicet Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ACET's full-year earnings has moved 16.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ACET has returned 2.6% so far this year. Meanwhile, the Medical sector has returned an average of 0.8% on a year-to-date basis. As we can see, Adicet Bio, Inc. is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Biodesix, Inc. (BDSX - Free Report) . The stock has returned 231.6% year-to-date.
Over the past three months, Biodesix, Inc.'s consensus EPS estimate for the current year has increased 19.7%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adicet Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 440 individual stocks and currently sits at #155 in the Zacks Industry Rank. Stocks in this group have gained about 6.2% so far this year, so ACET is slightly underperforming its industry this group in terms of year-to-date returns.
Biodesix, Inc., however, belongs to the Medical Services industry. Currently, this 72-stock industry is ranked #95. The industry has moved -2.3% so far this year.
Investors with an interest in Medical stocks should continue to track Adicet Bio, Inc. and Biodesix, Inc.. These stocks will be looking to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adicet Bio, Inc. (ACET - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adicet Bio, Inc. is a member of our Medical group, which includes 920 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adicet Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ACET's full-year earnings has moved 16.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ACET has returned 2.6% so far this year. Meanwhile, the Medical sector has returned an average of 0.8% on a year-to-date basis. As we can see, Adicet Bio, Inc. is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Biodesix, Inc. (BDSX - Free Report) . The stock has returned 231.6% year-to-date.
Over the past three months, Biodesix, Inc.'s consensus EPS estimate for the current year has increased 19.7%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adicet Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 440 individual stocks and currently sits at #155 in the Zacks Industry Rank. Stocks in this group have gained about 6.2% so far this year, so ACET is slightly underperforming its industry this group in terms of year-to-date returns.
Biodesix, Inc., however, belongs to the Medical Services industry. Currently, this 72-stock industry is ranked #95. The industry has moved -2.3% so far this year.
Investors with an interest in Medical stocks should continue to track Adicet Bio, Inc. and Biodesix, Inc.. These stocks will be looking to continue their solid performance.